|
 |
| home > epc > Summer 2002 |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor |
|
|
|
|
| At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EPC provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of pharmaceuticals, take a look below at the range of articles featured in this issue of EPC |
 |
| |
|
|
| In his Editor's Letter, Dr Graham Hughes provides a brief summary of the articles in this issue of EPC |
|
|
|
|
| Brian Arnot, Business Development Executive at Tepnel Scientific Services, considers the key drivers for customers when choosing an outsourcing partner, in Making the Right Choice in Pharmaceutical Outsourcing |
|
|
| In Financing Within the SMO Industry, Dr Henk Mulder, Founder of Osteosupport, offers some guidance on how to balance an SMO's income with its costs |
|
|
| Many pharmaceutical companies are currently exploring, evolving, reshaping and developing a variety of ideas on how to better use e-mail internally. Alan Slater, Freelance International Consultant in Pharmaceutical e-CRM, poses the question Marketing and Providing Health Information Via E-mail - Less is More? |
|
|
| We preview the forthcoming DIA meeting in Chicago in June, in The DIA's 38th Annual Meeting Offers More Programming Than Ever Before |
|
|
|
| In Leveraging Web-Based Clinical Trials to Support the Marketing Platform, Dr Michael Bowden, Dr Timothy Sprosen and Steve Mackenzie-Lawrie of Health Decisions, explore how new web-based clinical trial technologies can be used to meet marketing needs at the time of product launch and beyond |
|
|
| Milen Vrabevski, Medical Director of Comac Medical Ltd., explains how Bulgaria has gradually become an attractive location in which to conduct clinical research, in Clinical Trials in Bulgaria |
|
|
| In Offering a Global Service to Support Clinical Trials, Dr Daniel Chapple, Business Development Director and Paul Travis, Head of Central Laboratory Services at CentraLabS, explain how speed, quality and continuity of service are essential when analysing |
|
|
|
|
| Hilton Lord, Partner at Marks & Clerk looks at the opportunities and pitfalls for pharmaceutical companies looking to diversify into the US market, and asks What Do European Pharmaceutical Companies Need to Know in Order to Get Effective IP Protection in the US? |
|
|
| Pharmaceutical companies need to be aware of the regulatory changes that will be implemented over the next three years as a result of the adoption of the Clinical Trial Directive. Keren Winmill, Director of Clinical Trial Supplies at Penn Pharmaceutical Services, outlines The Trials and Tribulations of Importing Clinical Trials Materials into Europe |
|
|
| In Tracking and Audit Trailing, Mark Homer, Software Director at John Matchett Limited, highlights the regulatory pressure facing pharmaceutical companies and considers how management solutions can help |
|
|
|
| Philip Holt, Vice President of Life Sciences at Integic Corporation, explains how companies that can harness and manage the power of change will sustain the momentum of competitive advantage, in Change Management Through the Looking Glass |
|
|
| The last decade has seen an increasing interest in novel vaccine delivery systems, some with the potential to improve efficacy, safety profiles and standards of compliance. Dr Amber Gibson, Healthcare Analyst at Datamonitor, looks at Pain-Free Immunisation - The Future of Vaccine Delivery |
|
|
| Dr Roy Drucker, General Manager at Technomark Consulting Services Limited, reviews Drug Delivery Technologies: Innovations and Market Challenges - A Report in The Biotechnology Reports Series (PJB Publications Ltd) |
|
|
| In Nasal Drug Delivery - The Powder Advantage, Pete Lambert, Technical Manager for Britannia Pharmaceuticals Ltd, explores delivery to the nasal cavity as an alternative method and details the advances made so far |
|
|
| Improved blood compatibility is a desired feature for a variety of blood-contacting medical devices during clinical use. Dr Aron Anderson, Director of Drug Delivery, Amy Novak, Director of Haemocompatibility, and David Babcock, Associate Research Scientist, at SurModics, Inc. highlight Coating Advancements for Blood-Contacting Devices |
|
|
|
| Dr Graham Hughes and Julia Lloyd-Parks of Technomark Consulting Services Limited review the 14th Annual EuroMeeting of the Drug Information Association, which took place in Basel, Switzerland, in March |
|
|
|
| Professor Keith Wesnes, Chief Executive and Chris Edgar, Scientific Manager of Cognitive Drug Research Ltd review the Latest Developments in the Assessment of Human Cognitive Function in Clinical Trials |
|
|
| Transforming data into knowledge is a new frontier for drug discovery. Gareth Roberts, Co-Founder, and Jonathan Swinton, Bioinformatics Researcher at Proteom, explain why, in In Silico Proteomics - Evolution of Bioinformatics into Biomagic |
|
|
|
| Logistics can account for 50 per cent of study budgets, especially for trials involving infectious diseases with anti-infectives. David Cocker of MDCPartners presents The Case for Improved Clinical Logistics - The Buck Stops Here |
|
|
|
| Brian Dakin, Director of the Project Management Office at CB Technologies, Inc, explains how the use of EDC as an internal application for clinical trials is continuing to gain momentum, and asks Are You Ready for EDC Technology Transfer? |
|
|
| In Informatics Support for Electronic Records and Signatures in the European Pharmaceutical Industry, Peter Boogaard, European Applications Manager at Applied Biosystems, reflects on the practical impact of 21 CFR Part 11 100 Wolfgang Oestreich, Managing Director of Dr Oestreich + Partner, offers some advice on Why, When and How to Implement Electronic Data Capture - Core Decision Points |
|
|
| As Internet use spreads rapidly throughout the world, the barriers to deploying EDC are quickly disappearing. Mark Wren, Director of eService and Support, and Martin Young, Professional Services Director for Phase Forward, highlight how Global EDC Adoption is an increasingly attractive approach for sponsors |
|
|
| Liz Rolison, Vice President of PPD Informatics, the Clinical Data Consulting Services and Software Solutions Division of PPD Development, reflects on Application Service Providers - Making the Best in Clinical Research Technology Available and Affordable |
|
|
|
|
|
 |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Announces Plans to Implement XcelodoseTM Technology in the Production of Early Stage Clinical Trial Materials
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today plans to implement Xcelodose technology at its formulations development facility, ApiCross Drug Delivery Technologies. Xcelodose technology is a powder micro-dosing system developed by Meridica. This technology offers a unique powder dispensing system for small-scale capsule filling and ultimately assists in conserving valuable research material as well as reducing various Preformulation activities.
More info >> |
|
__________________________
__________________________
__________________________
__________________________
|
